The revived 340B rebate model pilot is the Health Resources and Services Administration’s second attempt to move a subset of 340B drugs from an upfront discount to a retrospective manufacturer rebate. HRSA published the new notice in the Federal Register on August 3, 2026, set a January 1, 2027 implementation date, and applied it to the drugs selected under the Medicare Drug Price Negotiation Program. For covered entities, the core question is cash flow: instead of buying at a discounted 340B ceiling price, participating hospitals will pay wholesale acquisition cost (WAC) at purchase and wait for a rebate after dispensing. This article explains the new development and how to prepare.
This piece is a sequel to our earlier analysis, Court Vacates the 340B Rebate Pilot: What Providers Must Know. That post covered the original pilot’s collapse. Here we focus on what changed and what covered entities should do now that a revised version is moving forward.
From Vacated to Revived: A Short Timeline
The first version of the pilot did not survive judicial review. A federal court in Maine granted a preliminary injunction in late December 2025, and the program was formally vacated and remanded on February 10, 2026, after HHS declined to keep fighting. The court’s central concern was that HRSA had not followed proper Administrative Procedure Act (APA) process.
HRSA did not abandon the concept. In February 2026, the agency issued a Request for Information seeking public input on using rebates to deliver 340B pricing, and it drew more than 2,400 comments. That feedback shaped the revised design.
On July 31, 2026, HHS announced the revised pilot, followed by the formal Federal Register notice on August 3, 2026. The agency framed the change as a response to the procedural defects the court identified, adding notice, dispute resolution, and resubmission provisions intended to satisfy APA requirements. Whether those additions hold up is an open question, because hospital groups have signaled they are weighing further legal action.
How the Revised 340B Rebate Model Pilot Works
The mechanism is a reversal of how 340B has historically operated. Under the traditional model, a covered entity buys eligible drugs at or below the 340B ceiling price, capturing the savings at the point of purchase. Under the pilot, a participating covered entity buys the drug at WAC through normal distribution channels, dispenses it to an eligible patient, and then submits claims-level data to the manufacturer’s platform. The manufacturer pays a rebate equal to WAC minus the 340B ceiling price on the date of dispense, calculated at the unit level.
The scope is narrow but meaningful. The pilot applies to the National Drug Codes selected under the Medicare Drug Price Negotiation Program for initial price applicability years 2026 and 2027. That is roughly 10 drugs tied to 2026 and 15 tied to 2027, for a total of about 25 products. HRSA has estimated, based on 2025 data, that these products represent about 5.5 percent of total 340B sales. Program parameters are published on the HRSA 340B rebate model pilot program page, which covered entities should monitor for updated guidance and the final selected-drug list.
Timing is compressed. Manufacturers wanting to participate had to submit plans to HRSA by August 24, 2026, with agency approvals expected by roughly September 24, 2026. The pilot then goes live January 1, 2027. Under the notice, covered entities have at least 45 calendar days from the date of dispense to submit the required claims-level data, and manufacturers must pay an approved rebate, or issue a documented denial, within 10 calendar days of a completed submission.
Cash-Flow and Accounting Effects of the 340B Rebate Model Pilot
The financial exposure is straightforward to describe and harder to absorb. When a covered entity buys at WAC instead of the 340B ceiling price, it fronts the full undiscounted cost of every affected unit and recovers the spread only after dispensing, submitting compliant data, and waiting for the manufacturer to pay. Even with a 10-day payment requirement, the entity carries a receivable it never carried before, and the gap between purchase and reimbursement is real working capital.
The affected drugs make the strain worse than the 5.5 percent sales figure suggests. Medicare-negotiated drugs skew toward high-cost specialty products, so a small share of units can represent a large share of dollars tied up at any moment. For hospitals and clinics already operating on thin margins, that concentration matters.
Denials and disputes add a second layer of risk. Any rebate that is rejected, delayed, or contested does not simply reduce margin; it converts a predictable discount into a collections exercise. Entities that lack clean claims data or a reliable submission process will see more denials and slower cash. This is where documentation discipline stops being a compliance nicety and becomes a treasury function.
How Covered Entities Should Prepare
Start by confirming exposure. Pull utilization for the roughly 25 negotiated drugs across the relevant applicability periods and quantify how many units and dollars would shift from an upfront discount to a delayed rebate. Entities that dispense little of the affected portfolio may see minimal impact, while those with meaningful volume should model the receivable and its timing.
Next, stress-test working capital. Build a simple cash model that assumes you pay WAC at purchase and receive rebates on a lag, then layer in a realistic denial rate. If the model shows a liquidity pinch, address it before January 1, 2027 through a line of credit, adjusted purchasing cadence, or reserve planning. Our cost report preparation work often surfaces exactly this kind of timing mismatch between when costs are incurred and when reimbursement lands.
Tighten data and documentation now. The rebate depends on clean, claims-level data submitted on time, so any weakness in your dispensing records, patient eligibility documentation, or 340B compliance program will translate directly into denied or delayed cash. Reconcile your inventory and dispensing systems, and make sure your team can produce the required data fields without manual scrambling.
Finally, coordinate finance, pharmacy, and compliance in one room. This is not a pharmacy-only change or a finance-only change; it touches purchasing, dispensing, claims, treasury, and audit readiness at once. Behavioral health providers and other safety-net organizations that rely on 340B savings should treat this as an operational project with an owner and a deadline. If you need help sizing the impact or building the model, our behavioral health team works with these providers on reimbursement and cash-flow planning.
Accounting and Reporting Considerations
The switch from an upfront discount to a retrospective rebate changes how the transaction lands in your books, not just when the cash arrives. Under the traditional model, the discount is embedded in inventory cost at purchase. Under the pilot, you record inventory at WAC and recognize a rebate receivable once the dispensing event and submission establish a valid claim.
That receivable needs its own controls. Track each expected rebate against the manufacturer’s actual payment, age the balances the way you would any other receivable, and reserve for the portion you reasonably expect to be denied or delayed. Without that discipline, the difference between booked rebates and collected cash can quietly overstate margin.
Cost reporting adds another wrinkle for hospitals. Because acquisition cost, dispensing data, and rebate recoveries now sit in different systems and time periods, reconciling them for the Medicare cost report and for 340B audit readiness takes more deliberate effort. Building the crosswalk before January 1, 2027 is far cheaper than untangling it during an audit.
Frequently Asked Questions
What is the 340B rebate model pilot?
It is an HRSA program that changes how covered entities receive 340B savings for a specific set of drugs. Rather than buying at the discounted 340B ceiling price, participating entities buy at wholesale acquisition cost and then receive a rebate from the manufacturer after dispensing. The revised version was published in the Federal Register on August 3, 2026.
When does the revived pilot take effect?
The implementation date is January 1, 2027. Manufacturers had to submit participation plans to HRSA by August 24, 2026, with agency approvals expected by roughly September 24, 2026.
Which drugs are covered by the pilot?
The pilot applies to drugs selected under the Medicare Drug Price Negotiation Program for initial price applicability years 2026 and 2027, roughly 25 products in total. HRSA has estimated these represent about 5.5 percent of total 340B sales based on 2025 data.
How is this different from the earlier pilot that was vacated?
A federal court vacated the original pilot on February 10, 2026, largely on Administrative Procedure Act grounds after a preliminary injunction in late December 2025. The revised pilot adds procedural safeguards such as notice, dispute resolution, and resubmission rights that HRSA says address the court’s concerns.
What is the main cash-flow risk for covered entities?
The entity pays full WAC at purchase and recovers the discount only after dispensing and submitting claims data, creating a receivable and a working capital gap. High-cost negotiated drugs concentrate that exposure, and any denied or delayed rebate turns a former discount into a collections problem.
Is the pilot final, or could it still change?
It is proceeding toward a January 1, 2027 start, but it remains contested. Hospital groups including the American Hospital Association have criticized the revised notice and are considering further options, so covered entities should prepare while monitoring for legal or regulatory developments.
